Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celltrion Biosimilar Package Strong, But How Many Indications Will It Get?

This article was originally published in PharmAsia News

Executive Summary

Like Zarxio before it, Celltrion’s biosimilar infliximab product Inflectra is coming before a US advisory committee having received a glowing review from FDA staff; but the key question seems to be how many of Remicade's indications will it be able to extrapolate.


Related Content

As They Look To The U.S., Celltrion And Hospira Win Approval For Remicade Biosimilars In Canada


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts